As a variety of novel cell- or gene-based therapies move closer to the clinic, or to market approval in a few cases, Bethan Hughes explores the rapidly evolving regulatory environment for such products.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Laying the regulatory path for advanced therapies. Nat Rev Drug Discov 7, 464–465 (2008). https://doi.org/10.1038/nrd2610
Issue Date:
DOI: https://doi.org/10.1038/nrd2610
This article is cited by
-
News in brief
Nature Reviews Drug Discovery (2009)
